Capacity Assessment of the National Medicines Regulatory Authority in a Low -Income Country.

IF 2 4区 医学 Q4 MEDICAL INFORMATICS Therapeutic innovation & regulatory science Pub Date : 2024-11-01 Epub Date: 2024-08-04 DOI:10.1007/s43441-024-00683-w
Fawzi Thomas, Onome T Abiri, Thomas A Conteh, Olufunsho Awodele
{"title":"Capacity Assessment of the National Medicines Regulatory Authority in a Low -Income Country.","authors":"Fawzi Thomas, Onome T Abiri, Thomas A Conteh, Olufunsho Awodele","doi":"10.1007/s43441-024-00683-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Access to medical products of the required efficacy, quality and safety is essential for everyone's health and wellbeing. To achieve this milestone, every country needs a robust and strong performing National Regulatory Authority (NRA) that is independent and outcome oriented. With the help of the World Health Organization (WHO), the global benchmarking tool is the gold standard used to assess the regulatory capacity of NRAs.</p><p><strong>Objectives: </strong>This study assessed the capacity of the National Medicines Regulatory Authority in Sierra Leone to perform its regulatory functions.</p><p><strong>Methods: </strong>This descriptive cross-sectional study used both qualitative and quantitative approaches. A self-administered questionnaire was used for the quantitative approach, and the qualitative aspect consisted of a desk review looking at key regulatory documents such as laws, regulations, policies, guidelines, standard operating procedures and reports. The data collection tool used was the WHO global benchmarking tool (GBT) for \"Evaluation of National Regulatory System of Medical Product Version VI.</p><p><strong>Results: </strong>The majority of the participants had a postgraduate degree (60%), and 72% had over 10 years of experience working at the NRA. Out of 251 sub-indicators assessed, 85 (34%) sub-indicators were fully implemented. Of the eight (8) functions assessed, sub-indicators related to clinical trial oversight and vigilance were the most implemented, with 67% and 62%, respectively. Of the 9 indicators assessed, 79% of the sub-indicators that are related to quality and risk management were implemented. The results of this study showed that PBSL operates at maturity level 1. The absence of laws and regulations that give PBSL the mandate to perform its regulatory functions was a major challenge even though other indicators were met. The study reported other challenges toward effective functioning, including but not limited to a lack of sufficient staff, weak enforcement of the sale of medicines and a poorly equipped quality control laboratory.</p>","PeriodicalId":23084,"journal":{"name":"Therapeutic innovation & regulatory science","volume":" ","pages":"1053-1060"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic innovation & regulatory science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43441-024-00683-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICAL INFORMATICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Access to medical products of the required efficacy, quality and safety is essential for everyone's health and wellbeing. To achieve this milestone, every country needs a robust and strong performing National Regulatory Authority (NRA) that is independent and outcome oriented. With the help of the World Health Organization (WHO), the global benchmarking tool is the gold standard used to assess the regulatory capacity of NRAs.

Objectives: This study assessed the capacity of the National Medicines Regulatory Authority in Sierra Leone to perform its regulatory functions.

Methods: This descriptive cross-sectional study used both qualitative and quantitative approaches. A self-administered questionnaire was used for the quantitative approach, and the qualitative aspect consisted of a desk review looking at key regulatory documents such as laws, regulations, policies, guidelines, standard operating procedures and reports. The data collection tool used was the WHO global benchmarking tool (GBT) for "Evaluation of National Regulatory System of Medical Product Version VI.

Results: The majority of the participants had a postgraduate degree (60%), and 72% had over 10 years of experience working at the NRA. Out of 251 sub-indicators assessed, 85 (34%) sub-indicators were fully implemented. Of the eight (8) functions assessed, sub-indicators related to clinical trial oversight and vigilance were the most implemented, with 67% and 62%, respectively. Of the 9 indicators assessed, 79% of the sub-indicators that are related to quality and risk management were implemented. The results of this study showed that PBSL operates at maturity level 1. The absence of laws and regulations that give PBSL the mandate to perform its regulatory functions was a major challenge even though other indicators were met. The study reported other challenges toward effective functioning, including but not limited to a lack of sufficient staff, weak enforcement of the sale of medicines and a poorly equipped quality control laboratory.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
低收入国家国家药品管理局的能力评估。
背景:获得具有所需疗效、质量和安全性的医疗产品对每个人的健康和福祉都至关重要。要实现这一里程碑,每个国家都需要有一个独立且以结果为导向的、稳健而强大的国家监管机构(NRA)。在世界卫生组织(WHO)的帮助下,全球基准工具成为评估国家药品监管局监管能力的黄金标准:本研究评估了塞拉利昂国家药品管理局履行监管职能的能力:这项描述性横断面研究采用了定性和定量两种方法。定量方法采用自填式调查问卷,定性方法包括案头审查关键监管文件,如法律、法规、政策、指南、标准操作程序和报告。所使用的数据收集工具是世界卫生组织的全球基准工具(GBT)"医疗产品国家监管体系评估第六版":大多数参与者拥有研究生学位(60%),72%的参与者拥有 10 年以上的国家药品监管局工作经验。在所评估的 251 项子指标中,有 85 项子指标(34%)得到了全面实施。在所评估的 8 项职能中,与临床试验监督和警惕性有关的次级指标的实施率最高,分别为 67% 和 62%。在评估的 9 项指标中,与质量和风险管理有关的次级指标有 79% 得到了落实。研究结果表明,PBSL 的运作成熟度为 1 级。尽管其他指标均已达到,但缺乏授权 PBSL 履行监管职能的法律法规仍是一大挑战。该研究报告还指出了在有效运作方面面临的其他挑战,包括但不限于缺乏足够的工作人员、药品销售执法不力以及质量控制实验室设备简陋。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic innovation & regulatory science
Therapeutic innovation & regulatory science MEDICAL INFORMATICS-PHARMACOLOGY & PHARMACY
CiteScore
3.40
自引率
13.30%
发文量
127
期刊介绍: Therapeutic Innovation & Regulatory Science (TIRS) is the official scientific journal of DIA that strives to advance medical product discovery, development, regulation, and use through the publication of peer-reviewed original and review articles, commentaries, and letters to the editor across the spectrum of converting biomedical science into practical solutions to advance human health. The focus areas of the journal are as follows: Biostatistics Clinical Trials Product Development and Innovation Global Perspectives Policy Regulatory Science Product Safety Special Populations
期刊最新文献
Comparison of Borrowing Methods for Incorporating Historical Data in Single-Arm Phase II Clinical Trials. Testing the Feasibility of a Digital Point of Care Solution for the Trusted Near Real-Time Bidirectional Exchange of Novel and Informative Adverse Event Information. Better Medicines for Children: Lessons Learnt and Share Learnings at the EFGCP Annual Paediatric Conferences. An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database for MAGnetic Expansion Control Spinal Rods. Principles for Evaluating the Efficacy and Safety of Ceramic Dental Implants in Japan.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1